Laekna Therapeutics $61 million Series D financing
We are advising Laekna Therapeutics in connection with its Series D financing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Bausch + Lomb $630 million IPO
We are advising Bausch Health on the separation of its eye health business into a new public company, Bausch + Lomb
Anthem $1.3 billion senior notes offering
The investment-grade notes are due 2032 and 2052
Deciphera Pharmaceuticals $172.5 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Market
HilleVax $200 million IPO
The shares are listed on the Nasdaq Global Select Market
Owens & Minor $600 million notes offering
The high-yield notes are due 2030
AN2 Therapeutics $69 million IPO
The shares are listed on the Nasdaq Global Select Market
Roche Holdings $5 billion notes offering
We advised Roche on the Rule 144A / Regulation S offering comprising five tranches of notes
Denali $400 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Silver Spike Acquisition Corp. II combination with Eleusis
We are advising the SPAC on the transaction